Zobrazeno 1 - 10
of 1 242
pro vyhledávání: '"D. Parenti"'
Publikováno v:
Osteoarthritis and Cartilage. 31:S8-S9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db526ec9d1e767e52e2bff6251e60ae0
https://doi.org/10.1016/j.joca.2023.01.492
https://doi.org/10.1016/j.joca.2023.01.492
Autor:
Sergio Schwartzman, Andrew Greenspan, Soumya D. Chakravarty, Stephen Xu, Jeffrey R. Curtis, Wayne Langholff, S. Kafka, Shawn Black, D. Parenti
Publikováno v:
Rheumatology and Therapy
Objective Evaluate tolerability and effectiveness of golimumab-IV versus infliximab in patients with rheumatoid arthritis (RA) in a real-world setting. Methods AWARE, a prospective, real-world, pragmatic, observational, multicenter, phase 4 study, en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94fc0852d4b03e239a3b80d5bc160e0
https://doi.org/10.1007/s40744-021-00354-4
https://doi.org/10.1007/s40744-021-00354-4
Publikováno v:
ARKIVOC, Vol 2006, Iss 8, Pp 74-82 (2006)
Externí odkaz:
https://doaj.org/article/26e1a37f7c0648bbba89fba65eb521a1
Autor:
George W. Reed, Lorie Ellis, S. Kafka, D. Parenti, Robert P. Magner, Stanley Cohen, Kimberly J. Dandreo, Ying Shan, Joel M. Kremer, Raphael J. DeHoratius
Publikováno v:
Clinical Rheumatology. 38:2501-2508
Dose escalation of infliximab in both primary and secondary nonresponders is widely reported; however, the usefulness of dose escalation has been disputed. The objective of this analysis is to evaluate trends in clinical efficacy following multiple i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5fdf48fe08b44ff0f5b9334d12c991c
https://doi.org/10.1007/s10067-019-04543-z
https://doi.org/10.1007/s10067-019-04543-z
Autor:
Kim Hung Lo, S. Kafka, Philip J. Mease, Arthur Kavanaugh, Soumya D. Chakravarty, M. Elaine Husni, Elizabeth C. Hsia, L. Kim, D. Parenti
Publikováno v:
ACR Open Rheumatology
ACR Open Rheumatology, Vol 2, Iss 11, Pp 640-647 (2020)
ACR Open Rheumatology, Vol 2, Iss 11, Pp 640-647 (2020)
OBJECTIVE To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis. METHODS Patients were ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8dc529e6e40362f79bdb540a0b33c04
https://pubmed.ncbi.nlm.nih.gov/33073933
https://pubmed.ncbi.nlm.nih.gov/33073933
Autor:
Sergio Schwartzman, Jeffrey R. Curtis, Shawn Black, Clifton O. Bingham, Wayne Langholff, D. Parenti, Stephen Xu, S. Kafka
Publikováno v:
Rheumatoid arthritis – prognosis, predictors and outcome.
Background Pt reported outcomes (PROs) play a role in disease evaluation, therapeutic assessment and care of RA pts. The Pt Reported Outcomes Measurement Information System (PROMIS [P]) questionnaires developed by NIH have been used in RA clinical pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c31e79c6f57f3ef4353f43699de0bfda
https://doi.org/10.1136/annrheumdis-2018-eular.1800
https://doi.org/10.1136/annrheumdis-2018-eular.1800
Autor:
Soumya D. Chakravarty, M.E. Husni, A. Kavanaugh, P. J. Mease, D. Parenti, L. Kim, Elizabeth C. Hsia, Kim Hung Lo, S. Kafka, Diane D. Harrison
Publikováno v:
Saturday, 16 JUNE 2018.
Background GO-VIBRANT was a Ph3 trial of IV golimumab (GLM) in adult pts w/active PsA. Objectives To evaluate improvement in skin, nail psoriasis and Dermatology Life Quality Index (DLQI) w/IV GLM. Methods Adult bio-naive PsA pts w/active disease(≥
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41d4556b734dc8a48ad44c47efba79a6
https://doi.org/10.1136/annrheumdis-2018-eular.1766
https://doi.org/10.1136/annrheumdis-2018-eular.1766
Autor:
Elizabeth C. Hsia, Diane D. Harrison, Soumya D. Chakravarty, D. Parenti, Kim Hung Lo, Philip J. Mease, L. Kim, S. Kafka, Arthur Kavanaugh, M. Elaine Husni
Publikováno v:
Abstracts accepted for Publication.
Background GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) with active psoriatic arthritis (PsA). Clinically meaningful improvements in skin and nail psoriasis (PsO) and in Dermatology Life Quality index (DLQ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad484d8297ce9b435fc3c4a35842eb6e
https://doi.org/10.1136/annrheumdis-2019-eular.1282
https://doi.org/10.1136/annrheumdis-2019-eular.1282
Autor:
Douglas Conaway, Alan Kivitz, Vance Bray, Wayne Langholff, Stephen Xu, D. Parenti, Joy Schechtman, Aaron Broadwell, S. Kafka, Shawn Black
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a real-world assessment of intravenous golimumab (GLM) and intravenous infliximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b0a3ada77ce935d133b1eaf4114f6ea
https://doi.org/10.1136/annrheumdis-2019-eular.1753
https://doi.org/10.1136/annrheumdis-2019-eular.1753
Autor:
Wayne Langholff, Stephen Xu, Shawn Black, S. Kafka, Jeffrey R. Curtis, D. Parenti, Sergio Schwartzman, Clifton O. Bingham
Publikováno v:
Abstracts Accepted for Publication.
Background PROMIS (Patient Reported Outcomes Measurement Information System) has been used in rheumatoid arthritis (RA) patients (Pts) to assess disease activity across multiple domains (i.e. physical function, fatigue, pain interference). AWARE (Com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb2147e7f137fe868a98e2e0e4822a3c
https://doi.org/10.1136/annrheumdis-2019-eular.572
https://doi.org/10.1136/annrheumdis-2019-eular.572